RIVANNA's Accuro XV Ultrasound System Gains FDA Clearance for Musculoskeletal Imaging
RIVANNA has received FDA 510(k) clearance for its Accuro XV Diagnostic Ultrasound System, marking a significant regulatory milestone. This clearance allows the system's commercial use for musculoskeletal imaging in hospitals and medical clinics. The Accuro XV features AI-enabled capabilities, including BoneEnhance for enhanced bone visualization and CADe/x for automated fracture detection. These capabilities are being validated through a multi-site clinical study. The system aims to democratize access to high-quality imaging and reduce the burden on imaging resources in emergency settings. 
